IDYA vs UNH

IDEAYA Biosciences maintains a strong score, reflecting its pioneering role in synthetic lethality oncology, a field with immense unmet needs and significant market potential for 10x growth. The robust GSK and recent AstraZeneca partnerships validate its platform, providing critical non-dilutive funding and extending cash runway, which is vital for an early-stage biotech. The imminent topline resu...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...